Actemra and CP-690550 in Rheumatoid Arthritis: Can a Novel Agent Revolutionize Established Treatment Patterns?

— A Webinar from Decision Resources

Based on our 2009 Physician & Payer Forum report The Rheumatoid Arthritis Biologics Landscape: Differentiation and Reimbursement in a Crowded Market, Decision Resources is offering an exclusive webinar entitled Actemra and CP-690550 in Rheumatoid Arthritis: Can a Novel Agent Revolutionize Established Treatment Patterns? Because this webinar will feature major report findings, it is ONLY available to purchasers of this Physician & Payer Forum report.

Please contact us to learn how you can purchase this report and attend the webinar.

The entry of biologics with novel mechanisms of action has intensified competition in the rheumatoid arthritis (RA) drug market and has segmented the market for disease-modifying agents. Decision Resources surveyed 100 U.S. rheumatologists and 20 managed care organization (MCO) pharmacy directors to assess their attitudes and expectations surrounding current and emerging disease-modifying therapies for RA, including the much-anticipated novel oral agents.

This webinar, presented by Decision Resources Analyst Joanna Kim, M.Ed., will answer the following questions:

• Will a novel oral disease-modifying anti-rheumatic drug such as Pfizer’s CP-690550 enter the treatment sequence ahead of established biological agents? What attributes will drive positioning in the treatment sequence ahead of established TNF-alpha inhibitors and what attributes could contribute to positioning late in treatment?
• What pricing do MCO pharmacy directors believe an efficacious, novel oral agent can command in the RA market? How will the pricing of a novel oral agent affect the drug’s tier status in MCOs’ formularies?
• At what line of therapy will most rheumatologists use Roche/Chugai’s Actemra and how will its position in RA treatment shape its market potential? Can Actemra capture a share of the early-line biologics use currently dominated by TNF-alpha inhibitors?
• What tier status do MCO pharmacy directors anticipate for emerging biologics such as Actemra? Will novel agents secure formulary status comparable to TNF-alpha inhibitors and what attributes are most likely to drive formulary placement?

Ms. Kim will conduct a live Q & A session after the presentation.

Registration

Actemra and CP-690550 in Rheumatoid Arthritis: Can a Novel Agent Revolutionize Established Treatment Patterns?

November 18, 2009 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this Physician & Payer Forum report and attend the webinar, please
contact us using the information below.

Contact Us

In North America — Steve Silvestro at 781-296-2626 or ssilvestro@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2009 Decision Resources, Inc. All rights reserved.